Show simple item record

dc.contributor.authorMárquez Coello, María de las Mercedes 
dc.contributor.authorArizcorreta Yarza, Ana 
dc.contributor.authorRodríguez Pardo, María
dc.contributor.authorIllanes Álvarez, Francisco
dc.contributor.authorMárquez, Denisse
dc.contributor.authorCuesta Sancho, Sara
dc.contributor.authorGirón González, José Antonio 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2021-09-09T09:36:07Z
dc.date.available2021-09-09T09:36:07Z
dc.date.issued2021-05
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/10498/25327
dc.description.abstractThe objective of this work was to identify predictive factors of fibrosis regression after direct antiviral agents (DAAs) in HCV-monoinfected and HIV/HCV-coinfected patients. This was a prospective study of HCV-monoinfected (n=20), HIV/HCV-co-infected (n=66) patients and healthy controls (n=15). Patients had started DAAs and achieved sustained virological response. Liver stiffness (LS) and serum concentrations of profibrotic transforming growth factor (TGF)-beta 1 and CXC chemokine ligand 4 (CXCL4) and antifibrotic HGF hepatocyte growth factor (HGF) were analyzed at baseline (M0) and 12 months after starting DAAs (M12). A M12 LS achievement of <= 9.5 kPa was considered the cutoff point to discharge from a liver clinic. The LS decrease from M0 to M12 was 34%. No significant differences were observed in LS decline between HCV- and HIV/HCV-infected individuals. Changes of serum CXCL4, TGF-beta 1 and HGF levels did not correlate with LS improvement. 16 out from 56 patients (28%) with a baseline LS>9.5 achieved a M12 LS <= 9.5. HCV-monoinfected and HIV/HCV coinfected patients experienced a significant reduction of LS after sustained virological response. This improvement did not correlate with changes in serum profibrotic or antifibrotic markers. A 29% of those with a baseline LS>9.5 achieved a LS under this cutoff point.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherNATURE RESEARCHes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceSci Rep 11, 9824 (2021)es_ES
dc.titleModifications of liver stiffness and CXCL4, TGF-beta 1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1038/s41598-021-89370-6


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional